RFK Jr.’s Embattled FDA Chief on Thin Ice Over Chaos and Strife (1)

May 4, 2026, 4:52 PM UTC

Food and Drug Administration Commissioner Marty Makary was supposed to be one of President Donald Trump’s more conventional, qualified personnel picks, with sterling academic credentials and bipartisan support.

But just over a year into his tenure, those inside the agency that regulates roughly one-fifth of consumer spending in the US describe a culture rocked by staff clashes, leadership turmoil, industry backlash and an embattled, paranoid leader. Outside, drug companies say they’ve been blindsided by setbacks.

Some people familiar with the dynamics called the situation unsustainable. While no immediate ouster is planned, people familiar with the matter who requested anonymity to ...

Learn more about Bloomberg Law or Log In to keep reading:

See Breaking News in Context

Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.

Already a subscriber?

Log in to keep reading or access research tools and resources.